

# CLAIMS

1. A pharmaceutical composition comprising a therapeutically effective amount of a first compound, said first compound being a prostaglandin agonist, or a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug, and a therapeutically effective amount of a second compound, said second compound being a HMG-CoA reductase inhibitor, or a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug.
2. A pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable vehicle, carrier or diluent.
3. A pharmaceutical composition of claim 1 wherein said first compound is selected from PGD<sub>1</sub>, PGD<sub>2</sub>, PGE<sub>2</sub>, PGE<sub>1</sub>, PGF<sub>2</sub> and PGF<sub>2α</sub>.
4. A pharmaceutical composition of claim 1 wherein said first compound is selected from a selective EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4</sub> agonist.
5. A pharmaceutical composition of claim 1 wherein said first compound is selected from a selective EP<sub>2</sub> agonist, a selective EP<sub>4</sub> agonist and an EP<sub>2</sub>/EP<sub>4</sub> agonist.
6. A pharmaceutical composition of claim 1 wherein said first compound is selected from:
  - 2-(3-{[2-(3,5-dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiazole-4-carboxylic acid;
  - 2-(3-{[3-(3-chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-thiazole-4-carboxylic acid;
  - (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid;
  - (3-(((2-(3,5-dichloro-phenoxy)-ethyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid;
  - (3-(((4-dimethylamino-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid; and
  - 7-[(4-butyl-benzyl)-methanesulfonyl-amino]-heptanoic acid,
 prodrugs thereof and pharmaceutically acceptable salts of said compounds and said prodrugs.

7. A pharmaceutical composition of claim 1 wherein said second compound is selected from mevastatin, lovastatin, pravastatin, velostatin, simvastatin, fluvastatin, cerivastatin, dalvastatin, fluindostatin and atorvastatin, prodrugs thereof and pharmaceutically acceptable salts of said compounds or  
5 said prodrugs.

8. The pharmaceutical composition of claim 5 wherein said second compound is selected from mevastatin, lovastatin, pravastatin, velostatin, simvastatin, fluvastatin, cerivastatin, dalvastatin, fluindostatin and atorvastatin, prodrugs thereof, and pharmaceutically acceptable salts of said compounds  
10 and said prodrugs.

9. The pharmaceutical composition of claim 6 wherein said second compound is selected from mevastatin, lovastatin, pravastatin, velostatin, simvastatin, fluvastatin, cerivastatin, dalvastatin, fluindostatin and atorvastatin, prodrugs thereof and pharmaceutically acceptable salt of said compounds  
15 and said prodrugs.

10. The pharmaceutical composition of claim 1 wherein said second compound is atorvastatin, prodrug thereof and pharmaceutically acceptable salts of said compound and said prodrugs.

11. The pharmaceutical composition of claim 5 wherein said second  
20 compound is atorvastatin, prodrugs thereof and pharmaceutically acceptable salts of said compounds and said prodrugs.

12. The pharmaceutical composition of claim 6 wherein said second compound is atorvastatin, prodrugs thereof and pharmaceutically acceptable salts of said compound and said prodrugs.

25 13. The pharmaceutical composition of claim 6 wherein said second compound is atorvastatin calcium.

14. A method of treating cartilage defects or disorders or promoting wound healing comprising administering to a mammal:

a therapeutically effective amount of a first compound, said first  
30 compound being a prostaglandin agonist, prodrugs thereof and pharmaceutically acceptable salts of said prostaglandin agonist and said prodrugs; and

a therapeutically effective amount of a second compound, said second compound being a HMG-CoA reductase inhibitor, prodrugs thereof and pharmaceutically acceptable salts of said inhibitor and said prodrugs.

5        15. The method of claim 14 wherein said first compound is selected from PGD<sub>1</sub>, PGD<sub>2</sub>, PGE<sub>2</sub>, PGE<sub>1</sub>, PGF<sub>2</sub>, and PGF<sub>2α</sub>.

16. The method of claim 14 wherein said first compound is selected from a selective EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub> and EP<sub>4</sub> agonist.

10        17. The method of claim 14 wherein said first compound is selected from a selective EP<sub>2</sub> agonist, a selective EP<sub>4</sub> agonist and an EP<sub>2</sub>/EP<sub>4</sub> agonist.

18. The method of claim 14 wherein said first compound is selected from:

2-(3-{[2-(3,5-dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiazole-4-carboxylic acid;

15        2-(3-{[3-(3-chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-thiazole-4-carboxylic acid;

(3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid;

20        (3-(((2-(3,5-dichloro-phenoxy)-ethyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid;

(3-(((4-dimethylamino-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid; and

25        7-[(4-butyl-benzyl)-methanesulfonyl-amino]-heptanoic acid, prodrugs thereof and pharmaceutically acceptable salts of said compounds and said prodrugs.

19. The method of claim 14 wherein said second compound is selected from mevastatin, lovastatin, pravastatin, velostatin, simvastatin, fluvastatin, cerivastatin, dalvastatin, fluindostatin and atorvastatin, prodrugs thereof and pharmaceutically acceptable salts of said compounds and said prodrugs.

20. The method of claim 14 wherein said second compound is atorvastatin, prodrugs thereof and pharmaceutically acceptable salts of said compound and said prodrugs.

21. The method of claim 14 wherein said second compound is atorvastatin calcium.

22. The method of claim 18 wherein said second compound is atorvastatin, prodrugs thereof and pharmaceutically acceptable salts of said compound and said prodrugs.

23. The method of claim 18 wherein said second compound is atorvastatin calcium.

24. The method of claim 14 wherein said mammal is a human.

25. A kit comprising:

a. an amount of a first compound, said first compound being a prostaglandin agonist, prodrugs thereof and pharmaceutically acceptable salts of said compound and said prodrugs in a first dosage form;

b. an amount of a second compound, said second compound being a HMG-CoA reductase inhibitor, prodrugs thereof and pharmaceutically acceptable salts of said compound and said prodrugs in a second dosage form; and

c. a container.

26. The kit of claim 25, wherein said first compound is selected from:

2-(3-{[2-(3,5-dichloro-phenoxy)-ethyl]-methanesulfonyl-amino}-propyl)-thiazole-4-carboxylic acid; 2-(3-{[3-(3-chloro-phenyl)-propyl]-methanesulfonyl-amino}-propyl)-thiazole-4-carboxylic acid; (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid; (3-(((2-(3,5-dichloro-phenoxy)-ethyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid; (3-(((4-dimethylamino-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid; and 7-[(4-butyl-benzyl)-methanesulfonyl-amino]-heptanoic acid; prodrugs thereof and pharmaceutically acceptable salts of said compound and said prodrugs, and said second compound is selected from atorvastatin, prodrugs thereof and pharmaceutically acceptable salts of said compound and said prodrugs.

27. The kit of claim 25, wherein said second compound is atorvastatin or atorvastatin calcium.

28. A method of treating cartilage defects or disorders or promoting wound healing comprising administering to a mammal:

a therapeutically effective amount of a first compound, said first compound being (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid, a prodrug thereof or a pharmaceutically acceptable salt of said first compound or said prodrug; and

5 a therapeutically effective amount of a second compound, said second compound being atorvastatin, a prodrug thereof or a pharmaceutically acceptable salt of said second compound or said prodrug.

29. The method of claim 28 wherein the first compound is (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid,  
10 sodium salt and the second compound is atorvastatin calcium.